title: Oral mexiletine for lidocaine-responsive neonatal epilepsy.
abstract: We report a patient with lidocaine-responsive neonatal epilepsy treated successfully with oral mexiletine. The patient was a male neonate who had seizures since 2days of age. While his seizures were refractory to phenobarbital, lamotrigine, vitamin B6, and midazolam, they were controlled by continuous lidocaine infusion. Oral mexiletine at serum levels of 0.2-0.4μg/ml was used successfully for long-term treatment of his seizures. No delay in psychomotor development was observed at the last follow-up at 20months of age. No mutation was identified in any of four genes: SCN1A, SCN1B, KCNQ2, and KCNQ3. Our patient demonstrates that oral mexiletine can be useful for long-term treatment of patients with lidocaine-responsive epilepsy.
authors.affiliation: Department of Pediatrics, Juntendo University Faculty of Medicine, Japan; Department of Pediatrics, Juntendo Nerima Hospital, Japan. mknakaza@juntendo.ac.jp
authors.forename: Mika
authors.initials: M
authors.lastname: Nakazawa
authors.forename: Akihisa
authors.initials: A
authors.lastname: Okumura
authors.forename: Shinichi
authors.initials: S
authors.lastname: Niijima
authors.forename: Shintaro
authors.initials: S
authors.lastname: Yamashita
authors.forename: Kuriko
authors.initials: K
authors.lastname: Shimono
authors.forename: Shinichi
authors.initials: S
authors.lastname: Hirose
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Shimizu
mesh_terms: D000284:Administration, Oral; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage*; D004569:Electroencephalography; D004827:Epilepsy / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007231:Infant, Newborn; D007262:Infusions, Intravenous; D008012:Lidocaine / Q000008:administration & dosage; D008297:Male; D008801:Mexiletine / Q000008:administration & dosage*
chemical_list: D000889:Anti-Arrhythmia Agents; D008801:Mexiletine; D008012:Lidocaine